CDKN2A and Peri-Implantitis: Oral administration of DQ could reduce 70–90% the number of senescent cells (p19, p21, or p16 positive cells) and osteoclasts around the implants, resulting in decreasing implant mobility and detachment even in the peri-implantitis model.